Kexing Biopharm (688136.SH) submits H-share issue application to Hong Kong Stock Exchange and publishes application materials.
Covax Pharmaceutical (688136.SH) issued an announcement that the company has completed the listing process on the Hong Kong Stock Exchange on November 6, 2025.
Kexing Biopharm (688136.SH) announced that on November 6, 2025, the company submitted an application to the Hong Kong Stock Exchange Limited ("HKEX") for the issuance of H shares and listing on the main board of the HKEX. The application materials were published on the HKEX website on the same day. The application materials were prepared and published in accordance with the requirements of the Hong Kong Securities and Futures Commission ("SFC") and HKEX. They are draft versions, and the information contained in them may be updated and revised in a timely manner. Investors should not make any investment decisions based on the information included in the materials.
Related Articles
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
Bidding for Warner Bros. (WBD.US) enters a critical period, while Paramount Skydance (PSKY.US) speeds up the antitrust review process.
US Stock Market Move | Multiple departments issued letters to support the new consumption and financial consumption driving LexinFintech Holdings Ltd. Sponsored ADR Class A (LX.US) to rise by 6.04%.
Industry's First Rider Family Hospitalization Protection Implemented Meituan Upgrades Major Illness Care Plan Covering Over One Million Rider Families
